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Objective: To report a case of coexisting systemic lupus erythematosus (SLE) and sickle cell
disease (SCD) with a review of the literature on the topic.
Methodology: Case report and literature review of the association between SLE and SCD
through scientiﬁc articles in health sciences databases, such as LILACS, MEDLINE/Pubmed
and  Scielo, until May 2012. Descriptors used: 1. Sickle cell anemia; 2. Sickle cell disease; 3.
Systemic lupus erythematosus; 4. Hemoglobinopathies.
Results: The authors describe an association between SLE and SS hemoglobinopathy in an
eight-year-old female patient presentingarticular, hematologic and neuropsychiatric mani-
festations during clinical evolution. Forty-ﬁve cases of association between SLE and SCD are
described in literature, mostly adults (62.2%), women (78%) and with the SS phenotype in
78%  of the cases, and diverse clinical manifestations. Compared with our patient, articular,
hematologic and neuropsychiatric manifestations were present in 76%, 36% and 27% of the
cases, respectively.
Conclusion: SLE and SCD are chronic diseases that have several clinical and laboratory ﬁnd-
ings  in common, meaning difﬁcult diagnosis and difﬁculty in ﬁnding the correct treatment.
Although the association between these diseases is not common, it is described in literature,
so  it is imperative that physicians who treat such diseases be alert to this possibility.
© 2014 Elsevier Editora Ltda. All rights reserved.
Coexistência  de  lúpus  eritematoso  sistêmico  e  doenc¸a falciforme:  relato
de  caso  e  revisão  da  literatura
r  e  s  u  m  oPalavras-chave:
Anemia falciforme
Doenc¸a falciforme
Objetivo: relatar um caso de coexistência de lúpus eritematoso sistêmico (LES) e doenc¸a
falciforme (DF) com revisão da literatura sobre o tema.
Metodologia: relato de caso e pesquisa da associac¸ão entre LES e DF na literatura, através de
artigos cientíﬁcos nas bases de dados de ciências da saúde, como LILACS, MEDLINE/Pubmed
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Lúpus eritematoso sistêmico
Hemoglobinopatias
e Scielo, até maio de 2012. Descritores utilizados: 1. anemia falciforme; 2. doenc¸a falciforme;
3.  lúpus eritematoso sistêmico; 4. hemoglobinopatias.
Resultados: os autores descrevem a associac¸ão de LES e hemoglobinopatia SS em paciente
do  sexo feminino, oito anos, apresentando manifestac¸ões articulares, hematológicas e neu-
ropsiquiátricas durante a sua evoluc¸ão clínica. Na literatura são descritos 45 casos de
associac¸ão  entre LES e DF, sendo a maioria em mulheres (78%) adultas (62,2%), apresentando
fenótipo SS em 78% dos casos e com manifestac¸ões clínicas variadas. Comparando com a
nossa  paciente, manifestac¸ões articulares, hematológicas e neuropsiquiátricas, estiveram
presentes em 76%, 36% e 27% dos casos, respectivamente.
Conclusões: LES e DF são doenc¸as crônicas que apresentam diversos achados clínicos e
laboratoriais em comum, implicando em diﬁculdades diagnósticas e na correta conduc¸ão
terapêutica dessas doenc¸as. A associac¸ão entre essas enfermidades não é comum, mas está
descrita na literatura, por isso é importante que médicos que cuidam dessas enfermidades
estejam atentos para tal possibilidade.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
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Hntroduction
ystemic lupus erythematosus (SLE) is a multisystem autoim-
une disease with an incidence of 1.9 to 5.6 per 100,000
nhabitants,1 while sickle cell disease (SCD) is one of
he most common hereditary diseases, affecting mainly
lack individuals.2 SCD is characterized by a mutation
n the hemoglobin beta chain with formation of abnor-
al  hemoglobin (HbS), responsible for microcirculation
bstruction, ischemia, tissue necrosis and systemic organ
ysfunction.2
The coexistence of SCD and SLE is rarely described in lit-
rature, even in predominantly black populations, in which
he prevalence of both conditions is higher.3 Wilson et al.
ere the ﬁrst to report this association.4 Perhaps the defective
ctivation of the alternative complement pathway in sickle
ell patients and the increased risk of infections caused by
ncapsulated bacteria predispose this group to develop an
utoimmune disease.5
The clinical features of SCD and SLE may show similar
anifestations, such as the presence of fever, anemia, artic-
lar, renal, neurological and cardiopulmonary involvements
nd, consequently, diagnostic difﬁculties. Sickle cell patients
howing atypical symptoms or refractory response to conven-
ional treatment should be investigated for the possibility of
oexistence of diseases.6
In view of the uncommon occurrence of this association,
he authors describe an early childhood case and review the
reviously reported cases until May 2012.
ethodology
ase report and literature review of the association between
LE and SCD through scientiﬁc articles in health sciences
atabases, such as LILACS, MEDLINE/Pubmed and Scielo
ntil May 2012. Descriptors used: 1. Sickle cell anemia;
. Sickle cell disease; 3. Systemic lupus erythematosus; 4.
emoglobinopathies.Case  report
Female patient diagnosed with SS hemoglobinopathy since
birth, showing recurring, mild painful vaso-occlusive crises
responsive to traditional hydration and analgesia. She has
never received blood transfusions. At the age of nine, pain
symptoms intensiﬁed, mainly characterized by repeated
crises of acute and asymmetric polyarthritis of the knees,
wrists, elbows and ankles, initially attributed to SCD. The
clinical picture evolved with the development of photosen-
sitivity, asthenia and intermittent fever, with an episode of
generalized tonic-clonic seizure associated with transient left
hemiparesis. Laboratory tests: hemoglobin, 7.9 g/dL; hema-
tocrit, 25%; WBC, 12.000/mm3; platelet count, 374.000 mm3
(160-400.000); hemoglobin electrophoresis HbS 98.7% and
HbA2 1.26%; positive antinuclear antibody (ANA) 1:320 (homo-
geneous pattern); positive anti-dsDNA antibody; erythrocyte
sedimentation rate, 68 mm (<20); C-reactive protein, 71 units
(< 6); rheumatoid factor, anti-Sm, anti-SSA, anti-SSB, were all
negative as were viral serology. Serum C3, C4 and CH50 levels
were normal as were renal and liverfunctions. Cranial mag-
netic resonance imaging revealed an area of hypoperfusion in
the right temporal lobe. The study of the cerebrospinal ﬂuid
was normal. The patient had a sibling with sickle cell anemia
who died at the age of two from acute myocardial infarc-
tion, and has two maternal aunts diagnosed with cutaneous
lupus. She was diagnosed with SLE according to American
College of Rheumatology (ACR) criteria,7 and the possibility
of involvement of the central nervous system (CNS) by both
diseases (SLE and SCD) was discussed. The patient received
prednisone 2 mg/kg/day, hydroxychloroquine 5 mg/kg/day and
blood transfusions in order to reduce HbS < 30%. Due  to the
possibility that the neurological manifestation was secondary
to SCD we chose not to associate another immunosuppress-
ive agent. There was signiﬁcant reduction in joint pain, no
progression of the neurological condition and improvement of
hematological indices (HbS 60%; Hb 8.5 g/dL). Patient remains
asymptomatic, taking hydroxychloroquine and prednisone
5 mg/day.
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Table 1 – Coexisting systemic lupus erythematosus and sickle cell disease – literature review.
Reference Age/Sex Hb Type Articular
involvement
Serositis Renal
involvement
Neuropsychiatric
involvement
Malar
rash
Oralulcer Photosensitivity Discoid
lupus
Hematological
alterations
ANA
Current report 8/F SS + - - + - - - - + +
21 28/F SS + - + - + - + - + +
55/F SS - - + - - - - - + +
22 8/M SS + - - + + + - + - +
5 63/F SS + - - - - - + + - +
21/M SS + + + - - - - - + +
16/F SS + + - - - - + - - +
14 35/F AS - - + - - - - - - +
15 30/F SS + + + - - - - - - +
40/M SS + - - - - - - + - +
32/F SC - - - - - - - - + +
35/F SS + - + - - - - - - +
27/F SS + - - - - - - - - +
25/F SS + - + - - - - - - +
26/M SC + - - - - - - - - +
28/F SS + - + - - - - - - +
32/F SS + - - - - - - - - +
27/F SS + - - - - - - - - +
40/F SS + - - - - - - + - +
38/F SS + - - - - - - - - +
17/F SC + - - - - - - - + +
16 28/F SC + - + - - + - - - +
23/M SS + + - + + - - - - +
16/F SS + - - + - - - + - +
24/F SS - + + + - - - - - +
17 17/M SS + + + - + - - + - +
14/F SS + + - + + - - + + +
11/F S + + - + + - - - + +
7/F SS + - + - - - - + - +
9/M SS - + - + - - - - - +
31 18/F SS - - + + - - - - - +
9 29/M S 0- + + - - - - - - + +
33 10/F SS + + - - - - - - + +
19 15/M SS + + + - + - - - + +
6 16/F SS + + + - - - - - + +
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Discussion
Epidemiology  of  SLE  and  SCD
The coexistence of SCD and SLE is rarely described in the lit-
erature, probably due to the small number of cases. Because
of the overlapping of symptoms of both diseases, particularly
those related to the CNS, establishing a differential diagnosis
between the diseases is unquestionably difﬁcult. Until April
2012, 45 patients with SCD and SLE had been reported in
the MEDLINE database (Table 1). Thirty-ﬁve (78%) of these
patients were female, while 10 (22%) were male. The majority
of patients are adults (62.2%), with a mean age of 23 years-
old at diagnosis (variation: 4 to 63). This resembles the age
group of SLE patients proposed by Manzi, in which the dis-
ease developed during the ages of 15 to 45.8 SLE developed in
patients aged ≤16 in only 37.7% of the cases described. Among
patients with SCD and SLE, 33 (78%) had the SS phenotype. Due
to the coexistence of severe complications, life expectancy
of these individuals can potentially be reduced when com-
pared to that of individuals who are diagnosed with one of the
diseases.9 Treatment has also become a great challenge, since
there are no controlled and randomized trials (that address
the impact of SCD) of immunosuppressive drugs often used in
SLE.
Probable  etiology  for  coexistence  of  SCD  and  SLE
The infectious complications of SCD patients have a multifac-
torial etiology: splenic atrophy, reduced phagocytic capacity,
defective opsonization, reduced production of antibodies and
alternative complement pathway components. Some authors
have proposed that the deﬁciency of factors of the alterna-
tive pathway complement and recurring infections caused
by encapsulated bacteria could be the link between the
immune complex disease and hemoglobin S.10–12 However,
there had been no reduction of alternative complement path-
way components in this report or in others described in the
literature.6,13
Articular  manifestations
Articular disease were present in 35 patients (76%)
with SLE and SCD, corresponding to the most common
manifestation.5,6,9–11,13–22 The difﬁculty in diagnosing the
coexistence of these two diseases is due to the fact both have
articular manifestations. Hence, SCD patients’ joint com-
plaints are interpreted as vaso-occlusive crises, delaying the
diagnosis of SLE.6,17 In this study, the patient presented with
a clinical picture of an asymmetric, additive, non-deforming
polyarthritis unresponsive to analgesia and with prolonged
evolution. Such characteristics diverge from standard SCD
arthritis, which is usually short-term, monoarticular, acute
and recurrent.16 Thus, general practitioners, pediatricians,
hematologists and rheumatologists should be alert to the SCD
patients with unsatisfactory response to hydration, analgesia
and articular involvement pattern change in relation to the
initial picture, and consider the possibility of association with
other diseases, including SLE.3,6,17
 t o l .72  r e v b r a s r e u m a
Hematological  manifestations
Hematological disorders are common in both SCD and SLE.
Table 1 shows patients with anemia, leukopenia or thrombo-
cytopenia. In this review, 16 patients (36%) met  at least one
of these criteria.3,5,6,9,10,12,15,17–19,21–24 However, hematological
laboratory evaluation is not very speciﬁc and, separately, it
does not contribute to the clinical suspicion of coexistence of
both diseases.
In most cases, SLE anemia is initially normocytic and nor-
mochromic  and, if persistent, evolves into microcytosis and
hypochromia.1 Hemolytic anemia is only found in 13% of
the cases.25 On the other hand, the decreased hemoglobin in
SCD is more  important, reaching levels that range from 6 g
to 9 g/dL,25 particularly in cases of sickle cell anemia (HbSS).
Therefore, patients suffering from both diseases may show
more severe anemia due to the overlapping of pathophysio-
logical disorders.
Leukopenia is identiﬁed in 20% to 40% of cases of iso-
late SLE,1 including granulocytopenia andlymphopenia. These
ﬁndingsare caused by autoantibodies and by the systemic
involvement of the disease. In SCD, predominantly leuko-
cytosis and thrombocytosis are observed due to functional
asplenia around the age of ﬁve.16
Neuropsychiatric  manifestations
Cerebral infarction, intracranial hemorrhage, cognitive dys-
function and seizures are neuropsychiatric disorders common
to both SLE and SCD. The prevalence of neurological disorders
in SLE patients is estimated to be 50%, with large variation
among studies,26 while in SCD it occurs in 25% of patients.27,28
In SLE, hemorrhage, thrombosis associated with antiphospho-
lipid antibodies, hypertension and thrombocytopenia relate
to cerebrovascular accident,29 while in SCD the formation of
aneurysms and the accumulation of drepanocytes in brain
vessels promote increased adhesion, intimal hyperplasia and
limited endoluminal ﬂow.30 In Table 1, one can see that 12
patients (27%) with SLE and SCD had neuropsychiatric dis-
orders, including seizures, psychosis, cognitive disorders and
cerebrovascular accident, and only two patients did not have
the SS phenotype.10–12,14,16,17,22,23,31 Presumably, individuals
with both diseases, particularly of SS phenotype, are more
likely to develop cerebrovascular disease. However, identifying
its etiology is imperative for an effective treatment. Additional
tests are critical for this differentiation. Transcranial Doppler
ultrasonography is a valuable tool for assessing cerebral blood
ﬂow dynamic.30 The presence of antiphospholipid antibodies
associated with the increase of inﬂammatory markers may
suggest lupus etiology, requiring high doses of corticosteroids
and additional immunosuppressive agents.1
Renal  manifestations
Both SCD and SLE can cause progressive renal failure, particu-
larly juvenile SLE. Lupus nephritis is reported in 29% to 80% of
juvenile cases, depending on the specialty of the researchers,
if rheumatologists or nephrologists.1 The diagnosis of SLE in
sickle cell individuals could be neglected due to the over-
lapping of signals that suggest renal disorder. Proteinuria, 2 0 1 5;5 5(1):68–74
hematuria, hyperﬁltration, glomerulopathy, nephrotic syn-
drome and chronic renal failure occur in both diseases.
However, nephrotic syndrome is particularly interesting since
it occurs much more  often in SLE than in SCD.4 In Table 1, 21
patients (47%) developed renal disease attributed to the devel-
opment of the SLE.3,5,6,10,11,13–17,19,21,23 Sickle cell nephropathy
has a broad spectrum of pathological presentations. Glomeru-
lar hyperﬁltration, hemosiderin deposits, papillary necrosis,
cortical infarction, focal segmental glomerulosclerosis, mem-
branoproliferative glomerulonephritis with or without depo-
sition of immune complexes, tubular atrophy and interstitial
ﬁbrosis may occur.30 Due to the wide renal involvement vari-
ety in SCD, renal biopsy becomes a useful diagnostic method
for sickle cell patients with suspected coexistence of SLE.
Lupus renal involvement targets glomeruli in most cases,
with subendothelial immune deposits and proliferation of
mesangial cells.1 The deﬁnition of the etiology of the renal
involvement in patients with both SCD and SLE has different
implication with regard to morbidity, mortality and treatment
options.16
Immunologic  manifestations
Both SCD and SLE show important immunologic manifesta-
tions. Such involvement is mentioned in all case reports of
coexistence of both diseases. The ANA may be present in the
two diseases, being positive in almost 100% of SLE patients.1
Approximately 20% of SCD patients have positive ANA with
titers greater than 1:160;32 however, mechanisms related
to the development of antibodies in such patients remain
unknown.16 Nonetheless, in the case of the association of both
diseases, more  speciﬁc autoantibodies, e.g. anti-dsDNA, anti-
SM,  anti-SSA and anti-SSB, should be ordered to support the
diagnosis. Testing for antiphospholipid antibodies and lupus
anticoagulant are also suggested, although these are also more
commonly found in SLE than in SDC patients.23 Our patient
presented with a positive ANA and anti-dsDNA. Anti-Sm, anti-
SSA, anti-SSB were negative and C3, C4 and CH50 were within
normal levels.
Serositis
Serositis is a clinical manifestation observed in both SCD
(as a consequence of vaso-occlusive crises) and SLE patients,
present in 18 patients (42.8%) of this review.3,5,6,9–11,15–19,23 The
clinical similarities of these two diseases may delay the diag-
nosis of an underlying connective tissue disorder; pericarditis
in sickle cell patients is a possible evidence of an active sys-
temic autoimmune disease and/or an infectious process.33
Skin  manifestations
Cutaneous involvement is reported in 50% to 80% of SLE
patients at diagnosis and in 85% of patients during the
course of the disease.1 Skin manifestations may include malar
rash, photosensitivity, vascular skin lesions with nodules
and ulceration, palmar/plantar erythema, Raynaud’s phe-
nomenon, annular erythema, alopecia and, less often, discoid
lupus or lupus profundus.1 The characteristic cutaneous man-
ifestation in SCD is the presence of lower-limb ulceration. The
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ost common manifestation in patients with both SLE and
CD has not been reported yet.
The following cutaneous manifestations are described in
able 1: malar rash (26%), discoid lesions (21%), photosen-
itivity (9.3%) and oral ulcers (6.9%).5,9,10,12,16,17,19–23 These
eatures are uncommon in SCD patients and may facilitate
he diagnosis of association of the two diseases.5
onclusion
here is consensus among authors that physicians may face
iagnostic difﬁculties when treating a SCD patient who devel-
ps SLE. These are different diseases, both with greater
revalence among blacks and sharing similar clinical manifes-
ations during the course of the disease, delaying the diagnosis
f a systemic autoimmune disease in these patients. Another
onfounding factor is that approximately 20% of SCD patients
ave a positive ANA at higher titers.32
Due to microvascular occlusion and hemolytic anemia at
ariable levels, SCD patients will have clinical manifestations,
uch as severe localized or diffuse pain that may be associated
ith edema and erythema, as well as chest pain, pulmonary
nﬁltrates, cardiomegaly, congestive heart failure, abdominal
ain and other vaso-occlusive manifestations.2
The limited number of cases published in the literature on
he coexistence of SLE and SCD in the same individual does
ot allow stating if SCD patients are more  likely to develop
LE.
According to the ﬁndings shown in this review, the
resence of certain clinical features in SCD should alert
ediatricians, hematologists and rheumatologists to the
ossibility of SLE diagnosis, particularly articular manifesta-
ions unresponsive to usual supportive measures, recurrent
nd refractory neuropsychiatric manifestations (especially
f associated to the presence of antiphospholipid antibod-
es), presence of nephrotic proteinuria and, also, presence
f leukopenia and/or thrombocytopenia. Renal biopsy and
ssessment of the speciﬁc antibodies for SLE could be very
seful in these cases, just as positivity for other clinical man-
festations, such as malar rash, photosensitivity, oral ulcers,
lopecia and discoid lupus.
Prospective studies are required to clarify which mecha-
isms lead SCD individuals to develop SLE or if the coexistence
f these two diseases is a mere  coincidence.
onﬂicts  of  interest
he authors declare no conﬂicts of interest.
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